ACTION-1 (NCT05477576) is a 2-part, global, randomized, controlled, open-label, phase 1b/3 trial of RYZ101 in advanced, well-differentiated SSTR+ GEP-NETs progressing after 177Lu-SSA therapy. Herein, we report results from the phase Ib portion of the trial....Confirmed objective response was seen in 5 evaluable pts....Initial data suggest promising efficacy.